SHR1459 Low Dose ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 222 | Primary nephrotic syndrome | 1 |
222. Primary nephrotic syndrome
Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05136456 (ClinicalTrials.gov) | November 5, 2021 | 17/11/2021 | Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy | A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR1459 Tablets in the Treatment of Primary Membranous Nephropathy (PMN) | Primary Membranous Nephropathy | Drug: SHR1459 Low Dose;Drug: SHR1459 High Dose;Drug: Placebo | Reistone Biopharma Company Limited | NULL | Recruiting | 18 Years | 75 Years | All | 60 | Phase 2 | China |